Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): results from a phase III, randomized, open‐label, efficacy–assessor‐blinded clinical trial*

Abstract

At week 52, risankizumab demonstrated superior efficacy and similar safety with less frequent dosing compared with secukinumab.